AI Drug Development Company Raises $237 Million

On 23 October New York based Pathos AI raised $237 million and reached a valuation of about $3 billion. The company is working with Bristol Myers Squibb and Tempus AI to use artificial intelligence and patient data to improve drug development. HPC can source healthcare AI, biotechnology and medical technology companies for pharmaceutical groups, investors and international partners.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.